A Score to Predict the Risk of Major Adverse Drug Reactions Among Multi-Drug Resistant Tuberculosis Patients in Southern Ethiopia, 2014–2019

References

• Wang W, Wang J, Zhao Q, et al. Contribution of rural-to-urban migration in the prevalence of drug resistant tuberculosis in China. Eur J Clin Microbiol Infect Dis. 2011;30(4):581–586. doi:10.1007/s10096-010-1125-6
   Web of Science ®Google Scholar
• Eshetie S, Gizachew M, Dagnew M, et al. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):1–12. doi:10.1186/s12879-017-2323-y
   Web of Science ®Google Scholar
• Girum T, Muktar E, Lentiro K, Wondiye H, Shewangizaw M. Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop Dis Travel Med V. 2018;4(1):1–12. doi:10.1186/s40794-018-0065-5
   Google Scholar
• Stop TB partner ship. Availabe from: http://www.stoptb.org/countries/tbdata.asp. Accessed May 02, 2021.
   Google Scholar
• Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3):1602308. doi:10.1183/13993003.02308-2016
   PubMed Web of Science ®Google Scholar
• World Health Organization. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient. 2012.
   Google Scholar
• Tola HH, Holakouie-Naieni K, Lejisa T, et al. Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis. PLoS One. 2019;14(6):e0218487. doi:10.1371/journal.pone.0218487
   PubMed Web of Science ®Google Scholar
• Schnippel K, Berhanu RH, Black A, et al. Severe adverse events during second-line tuberculosis treatment in the context of high HIV co-infection in South Africa: a retrospective cohort study. BMC Infect Dis. 2016;16(1):1–10. doi:10.1186/s12879-016-1933-0
   Web of Science ®Google Scholar
• Merid MW, Gezie LD, Kassa GM, Muluneh AG, Akalu TY, Yenit MK. Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study. BMC Infect Dis. 2019;19(1):1–12. doi:10.1186/s12879-019-3919-1
   Web of Science ®Google Scholar
• Carroll M, Lee M, Cai Y, et al. Frequency of adverse reactions to first-and second-line anti-tuberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis. 2012;16(7):961–966. doi:10.5588/ijtld.11.0574
   Web of Science ®Google Scholar
• Lorent N, Sebatunzi O, Mukeshimana G, Van den Ende J, Clerinx J. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. PLoS One. 2011;6(5):e19566. doi:10.1371/journal.pone.0019566
   PubMed Web of Science ®Google Scholar
• Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, et al. Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru. PLoS One. 2011;6(11):e27610. doi:10.1371/journal.pone.0027610
   PubMed Web of Science ®Google Scholar
• Abera W, Cheneke W, Abebe G. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study. Int J Mycobacteriol. 2016;5(1):14–20. doi:10.1016/j.ijmyco.2015.10.002
   Google Scholar
• Chiang Y-C, Lin Y-M, Lee J-A, Lee C-N, Chen H-Y. Tobacco consumption is a reversible risk factor associated with reduced successful treatment outcomes of anti-tuberculosis therapy. Int J Infect Dis. 2012;16(2):e130–e5. doi:10.1016/j.ijid.2011.10.007
   Web of Science ®Google Scholar
• Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S. Tuberculosis and nutrition. Lung India. 2009;26(1):9. doi:10.4103/0970-2113.45198
   PubMedGoogle Scholar
• Mouton JP, Njuguna C, Kramer N, et al. Adverse drug reactions causing admission to medical wards: a cross-sectional survey at 4 hospitals in South Africa. Medicine. 2016;95(19):e3437. doi:10.1097/MD.0000000000003437
   PubMed Web of Science ®Google Scholar
• Ahmad N, Javaid A, Sulaiman SAS, Afridi AK, Khan AH, Khan AH. Occurrence, management, and risk factors for adverse drug reactions in multidrug resistant tuberculosis patients. Am J Ther. 2018;25(5):e533–e540. doi:10.1097/MJT.0000000000000421
   Web of Science ®Google Scholar
• Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5(7):648–655.
   PubMed Web of Science ®Google Scholar
• Resende LSO, Santos-Neto ETD. Risk factors associated with adverse reactions to antituberculosis drugs. J Bras Pneumol. 2015;41(1):77–89. doi:10.1590/S1806-37132015000100010
   Web of Science ®Google Scholar
• Bogale L, Tsegaye T, Abdulkadir M, Akalu TY. Unfavorable treatment outcome and its predictors among patients with multidrug-resistance tuberculosis in Southern Ethiopia in 2014 to 2019: a multi-center retrospective follow-up study. Infect Drug Resist. 2021;14:1343–1355. doi:10.2147/IDR.S300814
   PubMed Web of Science ®Google Scholar
• Pavlou M, Ambler G, Seaman SR, et al. How to develop a more accurate risk prediction model when there are few events. BMJ. 2015;351.doi: 10.1136/bmj.h3868
   Web of Science ®Google Scholar
• Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988 Jun 3;240(4857):1285-93.
   Google Scholar
• Abdelbary BE, Garcia-Viveros M, Ramirez-Oropesa H, Rahbar MH, Restrepo BI. Predicting treatment failure, death and drug resistance using a computed risk score among newly diagnosed TB patients in Tamaulipas, Mexico. Epidemiol Infect. 2017;145(14):3020–3034. doi:10.1017/S0950268817001911
   PubMed Web of Science ®Google Scholar
• Alene KA, Viney K, Gray DJ, McBryde ES, Xu Z, Clements ACA. Development of a risk score for prediction of poor treatment outcomes among patients with multidrug-resistant tuberculosis. PLoS One. 2020;15(1):e0227100. doi:10.1371/journal.pone.0227100
   Web of Science ®Google Scholar
• Arroyo LH, Ramos ACV, Yamamura M. Predictive model of unfavorable outcomes for multidrug-resistant tuberculosis. Revista de Saude Publica. 2019;53:77. doi:10.11606/s1518-8787.2019053001151
   Web of Science ®Google Scholar
• Hasan O, Meltzer DO, Shaykevich SA, et al. Hospital readmission in general medicine patients: a prediction model. J Gen Intern Med. 2010;25(3):211–219. doi:10.1007/s11606-009-1196-1
   PubMed Web of Science ®Google Scholar
• Tang X-R, Li Y-Q, Liang S-B, et al. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 2018;19(3):382–393. doi:10.1016/S1470-2045(18)30080-9
   PubMed Web of Science ®Google Scholar
• Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham heart study): a community-based cohort study. Lancet. 2009;373(9665):739–745. doi:10.1016/S0140-6736(09)60443-8
   PubMed Web of Science ®Google Scholar
• Straney L, Clements A, Parslow RC, et al. Paediatric index of mortality 3: an updated model for predicting mortality in pediatric intensive care. Pediatr Crit Care Med. 2013;14(7):673–681. doi:10.1097/PCC.0b013e31829760cf
   PubMed Web of Science ®Google Scholar
• Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. 2000;84(10):548–552. doi:10.1055/s-0037-1614065
   Web of Science ®Google Scholar